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Vemurafenib has been approved since 2011 in the
United States for the treatment of advanced BRAF
V600emutated melanoma as first-line therapy.
Although it significantly prolongs overall and
progression-free survival, most patients relapse
within 6 to 8 months owing to acquisition of drug
resistance. New findings suggest that discontinuous
dose administration of vemurafenib might prolong
response to vemurafenib, but it is unclear whether
modified cell signalling or other mechanisms, such
as immune-mediated effects, are responsible for this
effect.
CASE REPORT
We report on a 72-year-old patient with a 1.5-mm
malignant melanoma on the right side of the chest, a
positive axillary sentinel lymph node, and 0/11
positive lymph nodes at complete lymph node
dissection diagnosed in August 2010. Adjuvant
interferon therapy was declined by the patient. In
December 2011, a cutaneous metastasis on the right
side of the chest was excised.
In April 2012, other cutaneous, pulmonary and
lymph node metastases occurred. Because of a
positive BRAF V600E mutation status, vemurafenib
(960 mg twice a day) was started. Eight days later,
therapy was terminated by the patient because of
side effects (angina pectoris, exanthema, and
bloody stool). Because the patient declined further
therapy, no subsequent treatment was performed.
Surprisingly, follow-up computed tomography
scans showed continuous partial regression of all
metastases during the subsequent months (Figs 1, Artment of Dermatology, Skin Cancer Center, University of
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13.and B and 2, A and B). Likewise, initially increased
levels of S100b, lactate dehydrogenase, and
C-reactive protein returned to normal 1 month
after vemurafenib treatment and remained within
normal levels. There is no evidence of tumor
progression 24 months after short-time treatment
with vemurafenib.DISCUSSION
In this case, a short-term administration of
vemurafenib might have caused profound and
long-lasting antitumor effects. Because tumor le-
sions continued to regress during the months after
therapy cessation, direct antitumor effects of ve-
murafenib are unlikely to account for this effect.
Instead, we suggest that immune responses may
play a crucial role, either because of the release of
tumor antigens from vemurafenib-induced mela-
noma cell death or direct immunomodulatory
effects of vemurafenib. Indeed, vemurafenib was
found to stimulate immune recognition by
increasing major histocompatibility complex
expression by tumor cells,1 elevating serum levels
of interferon gamma, chemokine ligand 4, and
tumor necrosis factor-a2 and restoring compro-
mised dendritic cell function,3 resulting in elevated
numbers of tumor-infiltrating lymphocytes in pa-
tients4 and enhanced antitumor activity of adoptive
immunotherapy in mice.5 Thus, short-term or inter-
mittent vemurafenib treatment may be considered
as an adjunct for melanoma immunotherapy
(eg, with cytotoxic T-lymphocyte antigen 4 or
phosphodiesterase-1 antibodies).Correspondence to: Heidrun Mitzel, MD, Universit€atsmedizin,
Department of Dermatology, Langenbeckstr.1, 55131 Mainz,
Germany. E-mail: heidrun.mitzel@unimedizin-mainz.de.
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Fig 1. Cutaneous metastases before (A) and 13 months after (B) short-term vemurafenib
treatment.
Fig 2. Pulmonary metastasis before (A) and 19 months after (B) short-term vemurafenib
treatment.
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